BIRC5 and neoplasm: Studies with primary patient samples have demonstrated i) an HLA-mediated T cell response to the survivin protein in CRC tumor cells (59), and ii) NK cell cytotoxicity directed against CRC tumor cells following immune cell activation or tumor cell priming (60).